Stock PCVX VAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
73.93 USD +1.86% Intraday chart for Vaxcyte, Inc. +0.67% +17.72%
May. 22 Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing MT
May. 14 Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Business Summary

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Number of employees: 254

Managers

Managers TitleAgeSince
Jeff Fairman FOU
 Founder 60 13-05-26
Grant Pickering FOU
 Founder 56 13-05-26
Andrew Guggenhime DFI
 Director of Finance/CFO 55 20-04-30
Jakub Simon CTO
 Chief Tech/Sci/R&D Officer - 22-10-10
Mikhail Eydelman CMP
 Compliance Officer 43 22-03-31
James Wassil COO
 Chief Operating Officer 54 19-11-30
Janet Graesser IRC
 Investor Relations Contact - 21-03-31
Elvia Cowan PRN
 Corporate Officer/Principal 51 22-06-30
Whitney Jones HRO
 Human Resources Officer - Jan. 15
Harpreet Dhaliwal PRN
 Corporate Officer/Principal - 21-09-28

Members of the board

Members of the board TitleAgeSince
Grant Pickering FOU
 Founder 56 13-05-26
Anne Drapeau BRD
 Director/Board Member 57 21-09-15
Heath Lukatch BRD
 Director/Board Member 56 18-04-30
K. Hirth BRD
 Director/Board Member 72 16-08-31
Halley Gilbert BRD
 Director/Board Member 54 20-03-31
Carlos Paya CHM
 Chairman 65 21-10-26
Teri Loxam BRD
 Director/Board Member 52 21-09-15
Jacks Lee BRD
 Director/Board Member 60 Nov. 26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 108,795,188 106,210,782 ( 97.62 %) 0 97.62 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.95 %
16,261,159 14.95 % 1 143 M $
Vanguard Fiduciary Trust Co.
8.950 %
9,737,254 8.950 % 684 M $
BlackRock Advisors LLC
8.103 %
8,816,135 8.103 % 620 M $
RA Capital Management LP
7.541 %
8,203,754 7.541 % 576 M $
Janus Henderson Investors US LLC
7.053 %
7,673,868 7.053 % 539 M $
Wellington Management Co. LLP
4.522 %
4,919,370 4.522 % 346 M $
Capital Research & Management Co. (Global Investors)
3.806 %
4,140,521 3.806 % 291 M $
T. Rowe Price Investment Management, Inc.
3.266 %
3,552,967 3.266 % 250 M $
STATE STREET CORPORATION
3.067 %
3,337,092 3.067 % 234 M $
T. Rowe Price International Ltd.
2.919 %
3,176,181 2.919 % 223 M $

Company contact information

Vaxcyte, Inc.

825 Industrial Road Suite 300

94070, San Carlos

+650 837 0111

http://www.vaxcyte.com
address Vaxcyte, Inc.(PCVX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
73.93 USD
Average target price
103.1 USD
Spread / Average Target
+39.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VAXCYTE, INC. Stock Vaxcyte, Inc.
+17.72% 8.04B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.93% 123B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.01% 111B
BIONTECH SE Stock BioNTech SE
-7.23% 23.63B
ARGENX SE Stock argenx SE
+1.98% 22.58B
GENMAB A/S Stock Genmab A/S
-14.29% 17.26B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.79% 17.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.63% 17.61B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.17% 13.55B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.42% 11.34B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PCVX Stock
  4. Company Vaxcyte, Inc.